- Citations, last 5 years
- 0
- Works, last 5 years
- 1
- h-index
- 10
- Scientists listed
- 0
- Grants since 2016
- 18
Grants received
2025–2028 · research · R44
Optimizing SIV reservoir depletion by Tendel bsAb-98
Ellen Elizabeth Sparger · Vital Therapies (United States) · funded by National Institutes of Health
2024–2025 · research · R44
Targeted Cerebral Spinal Fluid (CSF) Drug Delivery - Enclear Precision System
Marcie A Glicksman · Vital Therapies (United States) · funded by National Institutes of Health
2024 · research · R44
Targeted Cerebral Spinal Fluid (CSF) Drug Delivery - Enclear Precision System
Marcie A Glicksman · Vital Therapies (United States) · funded by National Institutes of Health
2024–2025 · research · R43
Smart CSF Delivery System for CNS Drug Therapy for Leptomeningeal Disease
Marcie A Glicksman · Vital Therapies (United States) · funded by National Institutes of Health
2024–2026 · research · R44
Targeted Cerebral Spinal Fluid (CSF) Drug Delivery - Enclear Precision System
Marcie A Glicksman · Vital Therapies (United States) · funded by National Institutes of Health
2024–2026 · research · R43
Smart CSF Delivery System for CNS Drug Therapy for Leptomeningeal Disease
Marcie A Glicksman · Vital Therapies (United States) · funded by National Institutes of Health
2024–2026 · research · R43
Smart CSF Delivery System for CNS Drug Therapy for Leptomeningeal Disease
Marcie A Glicksman · Vital Therapies (United States) · funded by National Institutes of Health
2023–2026 · research · R43
Genetic adjuvants to elicit neutralizing antibodies against HIV
Dennis J. Hartigan-O'Connor · Vital Therapies (United States) · funded by National Institutes of Health
2023–2025 · research · R44
GMP production and GLP safety of bidirectionally targeted SARS-CoV-2 booster vaccine
Ellen Elizabeth Sparger · Vital Therapies (United States) · funded by National Institutes of Health
2023–2025 · contract · N43
TFH-TARGETING GENETIC ADJUVANTS TO PROMOTE DURABLE ANTI-INFLUENZA STEM ANTIBODIES IN OLDER ADULTS.
Kentner Singleton · Vital Therapies (United States) · funded by National Institutes of Health
2023–2025 · research · R43
Genetic adjuvants to elicit neutralizing antibodies against HIV
Dennis J. Hartigan-O'Connor · Vital Therapies (United States) · funded by National Institutes of Health
2023–2025 · research · R44
GMP production and GLP safety of bidirectionally targeted SARS-CoV-2 booster vaccine
Ellen Elizabeth Sparger · Vital Therapies (United States) · funded by National Institutes of Health
2022–2025 · research · R41
CCR5 immunotoxins as components of HIV cure regimens
Dennis J. Hartigan-O'Connor · Vital Therapies (United States) · funded by National Institutes of Health
2022–2024 · research · R41
CCR5 immunotoxins as components of HIV cure regimens
Dennis J. Hartigan-O'Connor · Vital Therapies (United States) · funded by National Institutes of Health
2022–2023 · research · R43
Adipokine-enriched brown adipocytes for treating polycystic ovary syndromes
Yongxing "James" Liu · Vital Therapies (United States) · funded by National Institutes of Health
2021–2023 · research · R41
Use of polymer-peptide system to deliver cells for intervertebral disc regeneration
Francisco J Silva · Vital Therapies (United States) · funded by National Institutes of Health
2021–2022 · research · R41
Memory-promoting Ad vaccine for long-lived protection against SARS-CoV-2
Dennis J. Hartigan-O'Connor · Vital Therapies (United States) · funded by National Institutes of Health
2020–2021 · research · R41
Nucleic acid-based formulation of cytomegalovirus-vectored HIV vaccines
Dennis J. Hartigan-O'Connor · Vital Therapies (United States) · funded by National Institutes of Health
